image header

News Releases

News Releases

Nov 24, 2020

ALX Oncology Announces December 2020 Virtual Investor Conference Participation Read more

Nov 16, 2020

Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2 Expressing Breast Cancer Read more

Nov 12, 2020

ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights Read more

Nov 9, 2020

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors Read more

Nov 5, 2020

ALX Oncology to Present ALX148 Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting Read more

Nov 2, 2020

ALX Oncology Announces November 2020 Virtual Investor Conference Participation Read more

Oct 28, 2020

ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome Read more

Oct 14, 2020

ALX Oncology to Present ALX148 Clinical Data at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting Read more

Oct 6, 2020

ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board Read more

Sep 22, 2020

ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer Read more

Displaying 1 - 10 of 23